{"id":"carazolol","rwe":[{"pmid":"41485077","year":"2026","title":"Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most \"Ideal\" Anti-Cancer β-Blocker.","finding":"","journal":"Pharmacology research & perspectives","studyType":"Clinical Study"},{"pmid":"39046191","year":"2024","title":"Molecular Mechanism of the β(3)AR Agonist Activity of a β-Blocker.","finding":"","journal":"ChemPlusChem","studyType":"Clinical Study"},{"pmid":"38447156","year":"2024","title":"Determinants of Neutral Antagonism and Inverse Agonism in the β(2)-Adrenergic Receptor.","finding":"","journal":"Journal of chemical information and modeling","studyType":"Clinical Study"},{"pmid":"38129128","year":"2024","title":"The β-Blocker Carvedilol and Related Aryloxypropanolamines Promote ERK1/2 Phosphorylation in HEK293 Cells with K (A) Values Distinct From Their Equilibrium Dissociation Constants as β (2)-Adrenoceptor Antagonists: Evidence for Functional Affinity.","finding":"","journal":"The Journal of pharmacology and experimental therapeutics","studyType":"Clinical Study"},{"pmid":"38017062","year":"2023","title":"GPCR molecular dynamics forecasting using recurrent neural networks.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"tags":[{"label":"carazolol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-2 adrenergic receptor","category":"target"},{"label":"ADRB2","category":"gene"},{"label":"ADRB3","category":"gene"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"racemic carazolol","offLabel":[],"synonyms":["carazolol","DL-Carazolol","racemic carazolol"],"timeline":[],"brandName":"Racemic Carazolol","ecosystem":[],"mechanism":{"target":"Beta-2 adrenergic receptor, Beta-3 adrenergic receptor, Beta-1 adrenergic receptor","targets":[{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor"},{"gene":"ADRB3","source":"DrugCentral","target":"Beta-3 adrenergic receptor","protein":"Beta-3 adrenergic receptor"}],"modality":"Small Molecule","drugClass":"carazolol","explanation":"Imagine your body has a system of 'volume controls' that regulate how fast your heart beats and how much air you breathe. Carazolol is like a 'mute button' that turns down the volume on these controls, helping to slow down your heart rate and reduce airway constriction.","oneSentence":"Carazolol works by selectively binding to and blocking the beta-2 adrenergic receptor, which is involved in various physiological responses.","technicalDetail":"Carazolol acts as a competitive antagonist at the beta-2 adrenergic receptor, which is a G protein-coupled receptor that plays a key role in mediating the effects of catecholamines such as epinephrine and norepinephrine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/487","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARAZOLOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:09:36.893465","biosimilars":[],"competitors":[{"drugName":"acebutolol","drugSlug":"acebutolol","fdaApproval":"1984-12-28","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"arformoterol","drugSlug":"arformoterol","fdaApproval":"2006-10-06","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"atenolol","drugSlug":"atenolol","fdaApproval":"1981-08-19","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"betaxolol","drugSlug":"betaxolol","fdaApproval":"1985-08-30","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bisoprolol","drugSlug":"bisoprolol","fdaApproval":"1992-07-31","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bitolterol","drugSlug":"bitolterol","fdaApproval":"1984-12-28","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"bretylium","drugSlug":"bretylium","fdaApproval":"1986-03-06","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"brexpiprazole","drugSlug":"brexpiprazole","fdaApproval":"2015-07-10","patentExpiry":"Oct 12, 2032","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"carazolol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acebutolol","brandName":"acebutolol","genericName":"acebutolol","approvalYear":"1984","relationship":"same-target"},{"drugId":"arformoterol","brandName":"arformoterol","genericName":"arformoterol","approvalYear":"2006","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"atenolol","brandName":"atenolol","genericName":"atenolol","approvalYear":"1981","relationship":"same-target"},{"drugId":"betaxolol","brandName":"betaxolol","genericName":"betaxolol","approvalYear":"1985","relationship":"same-target"},{"drugId":"bisoprolol","brandName":"bisoprolol","genericName":"bisoprolol","approvalYear":"1992","relationship":"same-target"},{"drugId":"bitolterol","brandName":"bitolterol","genericName":"bitolterol","approvalYear":"1984","relationship":"same-target"},{"drugId":"bretylium","brandName":"bretylium","genericName":"bretylium","approvalYear":"1986","relationship":"same-target"},{"drugId":"brexpiprazole","brandName":"brexpiprazole","genericName":"brexpiprazole","approvalYear":"2015","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"006896","UNII":"29PW75S82A","CHEBI":"CHEBI:135261","INN_ID":"4036","RXNORM":"20192","UMLSCUI":"C0054636","ChEMBL_ID":"CHEMBL324665","KEGG_DRUG":"D07608","PUBCHEM_CID":"71739","IUPHAR_LIGAND_ID":"569","MESH_SUPPLEMENTAL_RECORD_UI":"C014382"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":139,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41485077","title":"Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most \"Ideal\" Anti-Cancer β-Blocker.","journal":"Pharmacology research & perspectives"},{"date":"2024 Dec","pmid":"39046191","title":"Molecular Mechanism of the β(3)AR Agonist Activity of a β-Blocker.","journal":"ChemPlusChem"},{"date":"2024 Mar 25","pmid":"38447156","title":"Determinants of Neutral Antagonism and Inverse Agonism in the β(2)-Adrenergic Receptor.","journal":"Journal of chemical information and modeling"},{"date":"2024 Jan 17","pmid":"38129128","title":"The β-Blocker Carvedilol and Related Aryloxypropanolamines Promote ERK1/2 Phosphorylation in HEK293 Cells with K (A) Values Distinct From Their Equilibrium Dissociation Constants as β (2)-Adrenoceptor Antagonists: Evidence for Functional Affinity.","journal":"The Journal of pharmacology and experimental therapeutics"},{"date":"2023 Nov 28","pmid":"38017062","title":"GPCR molecular dynamics forecasting using recurrent neural networks.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Racemic Carazolol, also known as CARAZOLOL, is a small molecule drug that targets the beta-2 adrenergic receptor. It belongs to the carazolol drug class and was originally developed by an unknown entity. The commercial status of CARAZOLOL is unclear, and it is not FDA-approved for any indications. Further information on its pharmacokinetics and safety profile is also unavailable. As a result, CARAZOLOL is not widely recognized in the pharmaceutical industry.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}